The Biological Safety Testing Market size is expected to grow at an annual average of 11% during 2021-2027. Biological safety testing refers to bioanalytical testing performed by pharmaceutical and biotechnology companies or contract research institutes in the pharmaceutical manufacturing/packaging sector and may include several disciplines such as pharmacology, toxicology, microbiology, etc. These testing procedures mainly focus on the safety of materials from the raw material stage, from intermediate to final product.
(Get 15% Discount on Buying this Report)
A full report of Biological Safety Testing Market is available at: https://www.orionmarketreports.com/biological-safety-testing-market/11466/
The following segmentation are covered in this report:
By Product & Services
- Consumables
- Instrument
- Services
By Application
- Vaccine Manufacturing
- Monoclonal Antibodies Manufacturing
- Cellular & Gene Therapy Products Manufacturing
- Blood and Blood Products Manufacturing
- Other Application
By Test Type
- Endotoxin Test
- Sterility Test
- Mycoplasma Tests
- Bioburden Tests
- Residual Host-Cell Proteins & DNA Detection Tests
- Virus Safety Test
Company Profile
- Eurofins Scientific
- Lonza
- Merck KGaA
- Promega Corporation
- Thermo Fisher Scientific
The report covers the following objectives:
- Proliferation and maturation of trade in the global Biological Safety Testing Market
- The market share of the global Biological Safety Testing Market supply and demand ratio, growth revenue, supply chain analysis, and business overview.
- Current and future market trends that are influencing the growth opportunities and growth rate of the Biological Safety Testing Market
- Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Biological Safety Testing Market
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
